Graphic pathographies can illustrate how overreliance on statistics can obscure the clinical relevance of patients’ experiences of anxiety when they’re presented with prognoses.

Physicians should be aware of the powerful impact celebrities’ cancer narratives can have on patients’ experiences of their illnesses and treatment decisions. Partnering with celebrities is one strategy for delivering evidence-based health information and messaging to the public.

In the 1910s, the American Medical Association fought quackery promoted in pamphlets for drugs and treatments for everything from teething to epilepsy.

Minimizing and managing risks of ENMs means considering whether and when existing legal frameworks offer sufficient protection.

Nanoscale products pose ethical, legal, and policy challenges to governing the use of products that integrate multiple mechanisms of therapeutic action.

The Trans-Pacific Partnership Agreement could affect low-income patients’ access to medicines in signatory countries by reducing generic competition.

When evaluating a 10-year-old with leukemia and chemo-induced heart failure for VAD placement, a team considers what to do.

Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions.

Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation.

Little claims data exists upon which to make informed decisions about loss control or to draw upon when developing risk mitigation strategies.